To learn more about how SLC6A14 contributed to PC development, we conducted in vivo experiments and found that tumor weights in the SLC6A14-deficient group were significantly lower than those in the sh-control group (Fig. 10G, H). Here, SLC6A14 is linked to neoplasm.